Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

Background: There is considerable variability in COVID-19 outcomes amongst younger adults and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium. Method: The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors. Findings: We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1.4, 95% confidence interval [CI] 1.2-1.6) and COVID-19 related mortality (HR 1.5, 95%CI 1.3-1.8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2.0, 95%CI 1.6-2.6), venous thromboembolism (OR 1.7, 95%CI 1.2-2.4), and hepatic injury (OR 1.6, 95%CI 1.2-2.0). Risk allele carriers [≤] 60 years had higher odds of death or severe respiratory failure (OR 2.6, 95%CI 1.8-3.9) compared to those > 60 years OR 1.5 (95%CI 1.3-1.9, interaction p-value=0.04). Amongst individuals [≤] 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31.8% (95%CI 27.6-36.2) were risk variant carriers, compared to 13.9% (95%CI 12.6-15.2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those [≤] 60 years improved when including the risk allele (AUC 0.82 vs 0.84, p=0.016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors. Interpretation: The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality and these are more pronounced amongst individuals [≤] 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management. Funding: Funding was obtained by each of the participating cohorts individually.

[1]  J. Todd,et al.  Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus , 2021, Nature Genetics.

[2]  Mattia G. Bergomi,et al.  Mapping the human genetic architecture of COVID-19 , 2021, Nature.

[3]  J. Marchini,et al.  Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals , 2021, The American Journal of Human Genetics.

[4]  V. Vasiliou,et al.  COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy , 2021, Human genomics.

[5]  W. Tan,et al.  Genome and epigenome editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus associated with severe COVID-19 , 2021, Signal Transduction and Targeted Therapy.

[6]  J. Anesi.  The advisory Committee on Immunization practices’ updated interim recommendation for allocation of COVID-19 vaccine—United states, December 2020 , 2021, American Journal of Transplantation.

[7]  A. Maghazachi,et al.  Chemokines and chemokine receptors during COVID-19 infection , 2021, Computational and Structural Biotechnology Journal.

[8]  G. Cook,et al.  The CXCR6/CXCL16 axis links inflamm-aging to disease severity in COVID-19 patients , 2021, bioRxiv.

[9]  A. Servín-Caamaño,et al.  Impact of liver enzymes on SARS-CoV-2 infection and the severity of clinical course of COVID-19☆ , 2021, Liver Research.

[10]  B. Bell,et al.  The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[11]  R. Baric.  Emergence of a Highly Fit SARS-CoV-2 Variant. , 2020, The New England journal of medicine.

[12]  Shaghayegh Haghjooy Javanmard,et al.  SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study , 2020, The Lancet Infectious Diseases.

[13]  R. Rezaee,et al.  Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality , 2020, The American Journal of Emergency Medicine.

[14]  B. Neale,et al.  Findings and insights from the genetic investigation of age of first reported occurrence for complex disorders in the UK Biobank and FinnGen , 2020, medRxiv.

[15]  Barbara B. Shih,et al.  Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.

[16]  C. Signorelli,et al.  Age-specific COVID-19 case-fatality rate: no evidence of changes over time , 2020, International Journal of Public Health.

[17]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[18]  G. Novelli,et al.  Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis , 2020, Human genomics.

[19]  D. Larremore,et al.  Model-informed COVID-19 vaccine prioritization strategies by age and serostatus , 2020, Science.

[20]  Georgia Salanti,et al.  Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis , 2020, medRxiv.

[21]  D. Cummings,et al.  Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries , 2020, medRxiv.

[22]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[23]  J. Merrill,et al.  Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications , 2020, Nature Reviews Rheumatology.

[24]  G. Dranitsaris,et al.  A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes , 2020, EClinicalMedicine.

[25]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[26]  S. Pääbo,et al.  The major genetic risk factor for severe COVID-19 is inherited from Neanderthals , 2020, bioRxiv.

[27]  C. von Kalle,et al.  COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.

[28]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[29]  Mike Clarke,et al.  A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[30]  The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic , 2020, European Journal of Human Genetics.

[31]  I. Amit,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[32]  J. Sterne,et al.  Collider bias undermines our understanding of COVID-19 disease risk and severity , 2020, Nature Communications.

[33]  L. Mombaerts,et al.  An interpretable mortality prediction model for COVID-19 patients , 2020, Nature Machine Intelligence.

[34]  F. Tubach,et al.  Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19 , 2020, Qeios.

[35]  M. Mckee,et al.  If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future , 2020, Nature Medicine.

[36]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[37]  C. Sudlow,et al.  Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population , 2017, American journal of epidemiology.

[38]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[39]  M. Fox,et al.  Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors , 2015, Amino Acids.

[40]  A. Tonkin.  Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. , 2014 .

[41]  Sharon R Grossman,et al.  Integrating common and rare genetic variation in diverse human populations , 2010, Nature.

[42]  J. Oosterwijk,et al.  Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age , 2010, Breast Cancer Research and Treatment.

[43]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[44]  B. Tycko,et al.  Apolipoprotein E ε4 and Age at Onset of Sporadic and Familial Alzheimer Disease in Caribbean Hispanics , 2006 .

[45]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .

[46]  B. Tycko,et al.  Apolipoprotein E epsilon4 and age at onset of sporadic and familial Alzheimer disease in Caribbean Hispanics. , 2006, Archives of neurology.